CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PROTECT project aims to enhance drug safety monitoring by developing new methods for proactive assessment of drug benefits and risks. It utilizes diverse data sources, including patient reports and electronic health records, to improve signal detection and evaluation in pharmacovigilance.
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs.
Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions.
The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Agency (EMEA), willdevelop and test methods of proactive monitoring of drug safety and benefit risk (B/…
THE EUROPEAN MEDICINES AGENCY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
